## (19) World Intellectual Property Organization

International Bureau





(43) International Publication Date 28 July 2005 (28.07.2005)

**PCT** 

## (10) International Publication Number WO 2005/068466 A1

(51) International Patent Classification<sup>7</sup>: C07D 487/04, A61K 31/5517, A61P 25/00

(21) International Application Number:

PCT/IB2005/000263

(22) International Filing Date: 5 January 2005 (05.01.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

0400700.1 13 January 2004 (13.01.2004) GB 60/544,866 13 February 2004 (13.02.2004) US

- (71) Applicant (for GB only): PFIZER LIMITED [GB/GB]; Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).
- (71) Applicant (for all designated States except GB, US): PFIZER INC. [US/US]; 235 East 42nd Street, New York, NY 10017 (US).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): RYCKMANS, Thomas [BE/GB]; Pfizer Global Research and Development, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).
- (74) Agents: WOOD, David, J. et al.; Pfizer Research and Development, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

## Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: COMPOUNDS USEFUL IN THERAPY



(57) Abstract: Compounds of formula (I), or a pharmaceutically acceptable derivative thereof, wherein: X represents NR or O; R represents hydrogen,  $C_{1-8}$  alkyl or  $SO_2[C_{,1-8}$  alkyl]; W represents N or CH; Y and Y' independently represent hydrogen, halogen, OH, CF<sub>3</sub>, OCF<sub>3</sub>, CN, NH<sub>2</sub>  $C_{1-8}$  alkyl,  $C_{1-8}$  alkyloxy or  $C_{3-8}$ cycloalkyl; Ring A represents a heterocyclic ring containing at least one nitrogen atom; Z represents a direct link,  $C_{1-8}$  alkyl or  $C_{3-8}$  cycloalkyl;  $R^1$  represents  $R^2$ ,  $OR^2$ ,  $OR^3$ - $R^4$ ,  $N(R^2)[C_{1-8}$  alkylene]<sub>a</sub> $R^4$ ; NCOR<sup>2</sup>, or  $SR^4$ ;  $R^2$  and  $R^4$  independently represent hydrogen,  $C_{3-8}$  cycloalkyl,  $CF_3$ , Ar or Het;  $R^3$  represents a direct link or  $C_{1-8}$  alkyl; is 0 or 1; Ar represents an aromatic ring, optionally

fused to a heterocyclic ring, and/or optionally substituted with one or more groups as described below; Het represents a heterocyclic ring optionally substituted with one or more groups as described below, and/or optionally fused to an aromatic ring which is optionally substituted with one or more groups as described below; at each occurrence  $C_{1-8}$ alkyl,  $C_{1-8}$ alkylene and  $C_{3-8}$ cycloalkyl may be independently optionally substituted with one or more groups as described below; substituent groups for Ar, Het,  $C_{1-8}$ alkyl,  $C_{1-8}$ alkylene and  $C_{3-8}$ cycloalkyl referred to the above are independently selected from hydrogen, halogen,  $C_{1-8}$ alkyl,  $C_{1-8}$ alkyloxy,  $S[C_{1-8}$ alkyl], CN, CF<sub>3</sub>, NH<sub>2</sub> and OH; are useful for treating anxiety, cardiovascular disease (including angina, atherosclerosis, hypertension, heart failure, edema, hypernatremia), dysmenorrhoea (primary and secondary), endometriosis, emesis (including motion sickness), intrauterine growth retardation, inflammation (including rheumatoid arthritis), mittelschmerz, preclampsia, premature ejaculation, premature (preterm) labor and Raynaud's disease.

